کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
6121696 | 1219037 | 2012 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Current management and recommendations for access to antiviral therapy of herpes labialis
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
POMOTCHSV-2HSV-1FamciclovirFDAAciclovir - آیکلوویرover-the-counter - بیش از حد ضدHerpes labialis - تبخال تبخالVersus - در مقابلFood and Drug Administration - سازمان غذا و داروValaciclovir - والاسیکلوویرHerpes simplex virus type 1 - ویروس هرپس سیمپلکس نوع 1herpes simplex virus type 2 - ویروس هرپس سیمپلکس نوع 2General practitioner - پزشک عمومی
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
میکروبیولوژی و بیوتکنولوژی کاربردی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Current management and recommendations for access to antiviral therapy of herpes labialis Current management and recommendations for access to antiviral therapy of herpes labialis](/preview/png/6121696.png)
چکیده انگلیسی
Herpes labialis is a common skin infective condition, worldwide, which is primarily caused by HSV-1. Recurrent episodes of herpes labialis, also known as cold sores, can be frequent, painful, long-lasting and disfiguring for infected patients. At present, there are two types of antivirals for the treatment of herpes labialis, topical and oral, which are available over the counter or as prescription-only. The aim of antiviral therapy is to block viral replication to enable shortening the duration of symptoms and to accelerate healing of the lesions associated with herpes labialis. This review examines the evidence for the effectiveness of current topical and oral antivirals in the management of recurrent episodes of herpes labialis. In most countries, oral antivirals for herpes labialis are available as prescription-only. However, in early 2010, the oral antiviral famciclovir was reclassified from prescription-only medicine to pharmacist-controlled status in New Zealand. The benefits and risks associated with moving an antiviral therapy for herpes labialis from prescription-only to pharmacist-controlled status are reviewed here, and the implications for patients, general physicians and pharmacists are considered.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Clinical Virology - Volume 53, Issue 1, January 2012, Pages 6-11
Journal: Journal of Clinical Virology - Volume 53, Issue 1, January 2012, Pages 6-11
نویسندگان
Anthony Cunningham, Paul Griffiths, Peter Leone, Adrian Mindel, Rajul Patel, Lawrence Stanberry, Richard Whitley,